Ginkgo Results Presentation Deck
CASE STUDY 1
Ginkgo is developing 8 molecules for Cronos through two major
programs, the first of which is expected to be commercialized this year CRONOS
GROUP
I
▪ Ginkgo Bioworks to design microorganisms which can produce desired "target cannabinoids" at an industrial scale
▪ 8 target cannabinoids to be produced by yeast via industrial fermentation
▪ Target production yields at a fraction of the cost of traditional cannabinoids production in plants: < $1,000 USD per KG
Cronos Group will have the exclusive right to use and commercialize the key patented intellectual property related to the
production of the target cannabinoids perpetually and globally
CANNABINOID
PRECURSORS
NATURALLY
OCCURRING IN PLANT
DECARBOXYLATION
Partnership Overview
CBGA
MAJOR
CANNABINOIDS
THCA CBDA CBCA
Į
THC
Į ↓
CBD
CBC
CBGVA
✓ 1
THCVA CBDVA CBCVA
Į
THCV
Program 1
Source: Cronos Group (FINAL Ginkgo Deal Announcement Presentation, September 4, 2018)
↓
CBDV
Program 2
↓
CBCV
"At this stage, we have all the necessary licenses to commercialize a
product using cultured cannabinoids produced in our Winnipeg
facility and we plan to be the first to market with a product that
leverages this technology in Canada later this year. We'll be using
cultured CBG as our first product introduced to the market,
enabled by our partnership with Ginkgo, and we expect the final
productivity target for CBG will be achieved in the coming weeks
prior to September 2021, as previously announced. We are making
strides to ensure that Cronos become synonymous with innovation.
Launching cultured rare cannabinoids as a broader long-term
approach to branding and product differentiation."
Partner
(signed 2018)
Program Goals
Progress to Date
Kurt Schmidt, President & CEO
Cronos Q2 2021 Earnings Call (August 6, 2021)
Collaboration in Brief
Cronos Group, a publicly traded Canadian
cannabis company
Design microorganisms that can produce
desired target cannabinoids through
industrial-scale fermentation
Cronos has announced commercial
production and upcoming market launch of
CBG (first of 8 molecules)
H1 UPDATE | AUGUST 2021
GINKGO BIOWORKS
17View entire presentation